Exyte has completed the integration of Pharmaplan, marking the full transition of the Pharmaplan brand to Exyte and unifying biopharma engineering capabilities under one organisation.

In September 2024, Exyte announced the acquisition of Pharmaplan to establish a European champion and deepen partnerships with Europe’s biotechnology and pharmaceutical sectors. Pharmaplan contributes a pan-European footprint of locations and specialist teams now operating within Exyte’s Biopharma and Life Sciences organisation.

“Bringing Pharmaplan fully into Exyte combines global delivery scale with five decades of life sciences process and GMP expertise. Our clients benefit from seamless EPC solutions, from concept design to compliant handover. We deliver with speed, precision, and reliability. Facilities are where pharmaceutical innovation becomes real,” said Dr Wolfgang Büchele, CEO, Exyte.

Since the transaction was announced, integrated teams from both companies have collaborated to align systems and standards, and to combine the best practices across all disciplines. Through close collaboration, ongoing projects progressed without interruption, and client relationships remained unaffected. Exyte has assumed, continues, and is deepening all relationships previously served by Pharmaplan.

Teams from both the organisations have also secured joint project wins beyond Europe, among others in Southeast Asia, underscoring the combined reach and credibility of the integrated setup.